VSTM - Verastem Oncology

-

$undefined

N/A

(N/A)

Verastem Oncology NasdaqCM:VSTM Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Location: 117 Kendrick Street, Needham, MA, 02494, United States | Website: https://www.verastem.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

386.2M

Cash

117.6M

Avg Qtr Burn

-28.79M

Short % of Float

31.17%

Insider Ownership

0.70%

Institutional Own.

78.88%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COPIKTRA (duvelisib) Details
Chronic lymphocytic leukemia, Small lymphocytic lymphoma , Cancer, Follicular lymphoma

Approved

Quarterly sales

Avutometinib (VS-6766) +/- Defactinib (AVMAPKI FAKZYNJA CO-PACK) Details
Ovarian cancer, Cancer, Low-Grade Serous Ovarian Cancer

Approved

Quarterly sales

Avutometinib (VS-6766) + LUMAKRAS (sotorasib) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Initiation

Avutometinib(VS-6766) (RAF/MEK Inhibitor) Details
Non-small cell lung carcinoma, Cancer

Failed

Discontinued

Avutometinib (VS-6766) + KRAZATI (adagrasib) Details
Non-small cell lung carcinoma, Cancer

Failed

Discontinued